WT2725
Total Payments
$634,944
Transactions
75
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $426,607 | 28 | 0 |
| 2017 | $208,336 | 47 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $630,944 | 74 | 99.4% |
| Consulting Fee | $4,000 | 1 | 0.6% |
Payments by Type
Research
$630,944
74 transactions
General
$4,000
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Study of WT2725 in Patients With Advanced Malignancies | Sunovion Pharmaceuticals Inc. | $426,607 | 0 |
| CLINICAL STUDY OF WT2725 IN PATIENTS WITH ADVANCED MALIGNANCIES | Sunovion Pharmaceuticals Inc. | $204,336 | 0 |
Top Doctors Receiving Payments for WT2725
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $630,944 | 74 |
| , MD | Medical Oncology | New York, NY | $4,000 | 1 |
Ad
Manufacturing Companies
- Sunovion Pharmaceuticals Inc. $634,944
Product Information
- Type Drug
- Total Payments $634,944
- Total Doctors 1
- Transactions 75
About WT2725
WT2725 is a drug associated with $634,944 in payments to 1 healthcare providers, recorded across 75 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2018. In 2018, $426,607 was paid across 28 transactions to 0 doctors.
The most common payment nature for WT2725 is "Unspecified" ($630,944, 99.4% of total).
WT2725 is associated with 2 research studies, including "Clinical Study of WT2725 in Patients With Advanced Malignancies" ($426,607).